<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23472">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031913</url>
  </required_header>
  <id_info>
    <org_study_id>HBV_FL</org_study_id>
    <nct_id>NCT02031913</nct_id>
  </id_info>
  <brief_title>Association Insulin Resistance and Hepatic Fibrosis in CHB and NAFLD</brief_title>
  <official_title>Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Boramae Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry for Health, Welfare and Family Affairs</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic steatosis and insulin resistance are associated with severity of fibrosis in
      non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C. However, clinical
      significance of steatosis and insulin resistance on fibrosis in chronic hepatitis B (CHB) is
      not well established. The aim was to investigate the relationship between insulin
      resistance, hepatic steatosis, and fibrosis in patients with CHB.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>2014 Years</target_duration>
  <primary_outcome>
    <measure>Insulin resistance and fibrosis indices</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement for insulin resistance and fibrosis index for hepatic fibrosis assessment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>CHB Patients Without Significant Alcohol Consumption or Other Known Liver Diseases, Who Showed Evidences of Hepatic</condition>
  <condition>Steatosis on Ultrasonography</condition>
  <arm_group>
    <arm_group_label>HBV without FL</arm_group_label>
    <description>Chronic hepatitis B without steatosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV with FL</arm_group_label>
    <description>Chronic hepatitis B patients with steatosis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis B patients who showed evidences of hepatic steatosis on ultrasonography
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B patients

          -  With evidences of hepatic steatosis on ultrasonography or pathology

        Exclusion Criteria:

          -  significant alcohol consumption or other known liver diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul Metropolitan Government Seoul National University</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Kim, M.D, PhD</last_name>
      <phone>8228702233</phone>
      <email>drwon1@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Saekyung Joo, M.D</last_name>
      <phone>821089619285</phone>
      <email>joo.sammy@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Won Kim, M.D, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Boramae Hospital</investigator_affiliation>
    <investigator_full_name>Won Kim</investigator_full_name>
    <investigator_title>M.D, PhD</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Hepatic fibrosis</keyword>
  <keyword>Steatosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
